CD4 and neoplasm: It was predicted that at steady-state trough, this would lead to 72% of patients with an RG6292 concentration above the Treg (%CD4) EC50 in the tumor (positive effect) and 40% of patients with an RG6292 concentration above the non-Treg (%CD4) EC50 in plasma (potentially negative effect; Fig. 2B).